A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaive patients with stage III and IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Teodorescu, G
Ciuleanu, T
Grigorescu, A
Firoiu, E
Muresan, DR
机构：
[1] Eli Lilly SRL, Bucharest, Romania
[2] Cluj Oncol Inst, Cluj Napoca, Romania
[3] Bucharest Oncol Inst, Bucharest, Romania
[4] Targoviste Cty Hosp, Targoviste, Romania
[5] Oradea Cty Hosp, Oradea, Romania
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81075-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S271 / S272
页数：2
相关论文
共 50 条
  • [31] Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer
    Mok, TSK
    Lam, KC
    Lee, C
    Zhang, L
    Wong, H
    Chan, ATC
    Yeo, W
    Yim, APC
    Chak, K
    Zee, B
    ONCOLOGY, 2005, 68 (4-6) : 485 - 492
  • [32] Gemcitabine plus carboplatin (GCB) versus cisplatin plus vinblastin (CV) in stage IIIB-IV non-small cell lung cancer (NSCLC).
    Grigorescu, AC
    Draghici, NI
    Gutulescu, N
    ANNALS OF ONCOLOGY, 2000, 11 : 110 - 110
  • [33] Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer
    Esteban, E
    Fra, J
    Corral, N
    Valle, M
    Carrasco, J
    Sala, M
    Puerta, J
    Estrada, E
    Palacio, I
    Vieitez, JM
    Buesa, JM
    Lacave, AJ
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 73 - 82
  • [34] Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer
    Emilio Esteban
    Joaquin Fra
    Norberto Corral
    Miguel Valle
    Juan Carrasco
    Marian Sala
    Javier Puerta
    Enrique Estrada
    Isabel Palacio
    Jose Maria Vieitez
    Jose Maria Buesa
    Angel Jimenez Lacave
    Investigational New Drugs, 2002, 20 : 73 - 82
  • [35] Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A phase II study
    Bretti, S
    Manzin, E
    Loddo, C
    Berruti, A
    Bombaci, S
    Vellani, G
    Celano, A
    ANTICANCER RESEARCH, 2002, 22 (05) : 3039 - 3043
  • [36] Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
    Hsu, Chiun
    Kuo, Sung-Hsin
    Hu, Fu-Chang
    Cheng, Ann-Lii
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Lin, Chia-Chi
    Huang, Tsu-Chen
    Yang, Pan-Chyr
    Yang, Chih-Hsin
    LUNG CANCER, 2008, 62 (03) : 334 - 343
  • [37] Gemcitabine (G) as a single drug versus gemcitabine plus vinerolbine (GV) for non-small cell lung cancer (NSCLC) stage IIIB and IV
    Raquel, Gerson
    Serrano, Alberto
    Villalobos, Alberto
    ANNALS OF ONCOLOGY, 2004, 15 : 195 - 195
  • [38] Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial
    Binder, Daniel
    Beinert, Thomas
    Schweisfurth, Hans
    Grah, Christian
    Temmestfeld-Wollbrueck, Bettina
    Schaeper, Christoph
    Mueller-Hagen, Gerit
    Schuermann, Dirk
    Suttorp, Norbert
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [39] Prospective randomized phase III trial of triplet chemotherapy with paclitaxel plus gemcitabine plus cisplatin compared to standard doublet chemotherapy with vinorelbine plus cisplatin in advanced non-small cell lung cancer
    Sorensen, J.
    Hansen, O.
    Vilmar, A.
    Frank, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Pemetrexed plus carboplatin versus gemcitabine plus carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer
    Gronberg, B. H.
    Bremnes, R.
    Aasebo, U.
    Brunsvig, P.
    Flotten, O.
    Hjelde, H.
    Wammer, F.
    Stornes, F.
    Tollali, T.
    Sundstrom, S. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345